FLT3 and acute myeloid leukemia: In AML and other cancer cells, FLT3-ITD inhibits Foxo3a[77,78], leading to Myc activation and glutaminolysis stimulation, which, in turn, generates anaplerotic substrates that fuel the TCA cycle, increasing citrate synthesis and its transport to cytoplasm.